Immune Algorithmics key facts
as of Oct 2026- Developer of an immune monitoring platform designed to assist in blood analytics and remote health monitoring.
- Immune Algorithmics is valued at approximately $34.4M as of Oct 2026 (last reported valuation).
- It has raised $24.6M; the latest was Later Stage VC ($11.4M) in Sep 2025.
- Notable investors include Creative Destruction Lab, SFC Capital, University of Toronto, University of Toronto Entrepreneurship, Hub71 — 12 tracked in total.
- Status: Privately Held (backing).
Immune Algorithmics's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Immune Algorithmics: the Monday email on marks, rounds and moves
Immune Algorithmics funding rounds
No funding rounds for Immune Algorithmics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Immune Algorithmics
12+Immune Algorithmics valuation
Immune Algorithmics's last reported valuation was $34.4 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
Immune Algorithmics investors
12 investors are on record for Immune Algorithmics, including Creative Destruction Lab, SFC Capital, University of Toronto and University of Toronto Entrepreneurship.
About Immune Algorithmics
Developer of an immune monitoring platform designed to assist in blood analytics and remote health monitoring. The company's technology utilizes artificial intelligence to perform remote blood testing and assess the risk from home for a particular condition, enabling doctors to monitor their patient's health in an enhanced manner.
- Sector
- Healthcare
- HQ
- Reading, United Kingdom
- Founded
- 2018
- Employees
- 38
- Website
- immunealgorithmics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.